Brentuximab Vedotin PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Brentuximab vedotin binds CD30 on target cells and is internalised. Lysosomal proteolysis releases monomethyl auristatin E (MMAE), which binds tubulin, disrupts microtubules, induces cell-cycle arrest and promotes apoptosis.
Indications / reported uses
EMA-authorised indications include selected CD30-positive Hodgkin lymphoma, systemic anaplastic large-cell lymphoma and cutaneous T-cell lymphoma settings; consult current product information for exact lines and combinations
Identification sources: The FDA ADCETRIS prescribing information reports an approximate molecular weight of 153 kDa and approximately four MMAE molecules per antibody. Because the drug-to-antibody ratio varies, the conjugate has no single exact molecular formula or molecular weight.
Brentuximab vedotin binds CD30 on target cells and is internalised. Lysosomal proteolysis releases monomethyl auristatin E (MMAE), which binds tubulin, disrupts microtubules, induces cell-cycle arrest and promotes apoptosis.
General use cases
EMA-authorised indications include selected CD30-positive Hodgkin lymphoma, systemic anaplastic large-cell lymphoma and cutaneous T-cell lymphoma settings; consult current product information for exact lines and combinations
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
Assessment scope
Project-specific PDE/ADE and OEL/OEB support
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Brentuximab Vedotin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Brentuximab Vedotin Permitted Daily Exposure (PDE) report (the Brentuximab Vedotin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Brentuximab Vedotin Occupational Exposure Limit (OEL) report (the Brentuximab Vedotin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.